Medical Devices UK

UK Neuromodulation for Depression Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

UK Neuromodulation for Depression Market Industry Trends and Forecast to 2034: Segmented by (Technology, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

UK · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $41.8 Mn Placeholder estimate
Estimate 2025 $45.0 Mn 2.9% of the global market
Projected 2034 $87.7 Mn 95% Adds $42.7 Mn over 9 forecast years
CAGR 2025–2034 7.7% Faster than 57% of 173 Medical Devices markets here
Key players 5
  • UK is 2.86% of the global market.
  • In Europe, the largest is Germany at $49.4 Mn.
  • Fastest growing: Russia at 10.2% a year.
  • UK ranks 2nd of 6 by size in Europe.

Market size projection

UK

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$42.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Neuromodulation for Depression Market market size by year, UK
YearMarket sizeChange that yearSince 2025
2024 (estimate) $41.8 Mn — —
2025 (base) $45.0 Mn +$3.2 Mn —
2026 (forecast) $48.5 Mn +$3.5 Mn +7.7%
2027 (forecast) $52.2 Mn +$3.7 Mn +16%
2028 (forecast) $56.2 Mn +$4.0 Mn +24.9%
2029 (forecast) $60.6 Mn +$4.3 Mn +34.5%
2030 (forecast) $65.2 Mn +$4.7 Mn +44.9%
2031 (forecast) $70.2 Mn +$5.0 Mn +56.1%
2032 (forecast) $75.6 Mn +$5.4 Mn +68.1%
2033 (forecast) $81.5 Mn +$5.8 Mn +81%
2034 (forecast) $87.7 Mn +$6.3 Mn +95%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

UK Neuromodulation for Depression Market Analysis at a glance
Market size, 2025$45.0 Mn placeholder estimate
Forecast, 2034$87.7 Mn placeholder estimate
Growth (CAGR), 2025–20347.7% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTechnology, setting and end user (see all)
Key playersNeuronetics, BrainsWay, Magstim, LivaNova PLC, Flow Neuroscience (see all)
Regulator in the UKMHRASource: Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.
Active clinical trials5 in the UKSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the UK. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The UK Neuromodulation for Depression Market Analysis Executive Summary

Neuromodulation for depression uses magnetic or electrical stimulation of the brain, such as TMS, to treat depression that does not respond to medicines.

Key segments of the neuromodulation for Depression market include technology (Transcranial Magnetic Stimulation, Electroconvulsive Therapy and Vagus Nerve Stimulation) and setting (Clinics, Hospitals and Home).

Bar chart: UK Neuromodulation for Depression market size, 2024–2034, placeholder estimates. $41.8 Mn in 2024, $45.0 Mn in 2025 and $87.7 Mn in 2034, 7.7% CAGR.
UK Neuromodulation for Depression market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

UK Neuromodulation for Depression Market Dynamics

Market Growth Drivers

More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the neuromodulation for Depression market. Governments and employers are investing more in mental health care.

Opportunity

Digital tools, new drug classes and care built into primary care and workplaces give the neuromodulation for Depression market strong room to grow worldwide.

Market Restraints

Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the neuromodulation for Depression market.

Competitive Landscape for Neuromodulation for Depression Market in UK

The neuromodulation for Depression market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Neuromodulation for Depression Market in UK

Neuromodulation for Depression in the UK: rules, payment and research

Medical devices sold in Great Britain need UKCA or CE marking and registration with the Medicines and Healthcare products Regulatory Agency (MHRA).⁠[1] The NHS gives care that is free at the point of use; in England, NICE advises which medicines and treatments the NHS should fund.⁠[2] ClinicalTrials.gov lists 5 studies on Neuromodulation for Depression that are recruiting, active or about to start in the UK.⁠[3] Suicide rate: 10.1 per 100,000 people in 2023, the latest WHO figure for the UK.⁠[4]

[1] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.

[2] National Institute for Health and Care Excellence. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the UK. Retrieved 12 Nov 2026.

[4] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how neuromodulation for Depression products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in UK.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Neuromodulation for Depression right now, from free public sources.

Clinical trials

5 active trials in the UK

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Magnetic Tides 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Neuromodulation for Depression in context

The UK compared

  • Suicide rate: 10.1 per 100,000 people (2023). World: 9.2 per 100,000 people (2023). 4th highest of the 6 countries we cover in Europe.[1]
  • Health spending per person: 5,860 US$ per person (2024). World: 1,317 US$ per person (2023). 2nd highest of the 6 countries we cover in Europe.[2]
  • Doctors: 3.30 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 5th highest of the 6 countries we cover in Europe.[3]

[1] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Neuromodulation for Depression market in the UK?
Placeholder estimate: about $45.0 Mn in 2025, rising to about $87.7 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Neuromodulation for Depression market in the UK growing?
Placeholder estimate: about 7.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Neuromodulation for Depression market report cover?
The report splits the market by technology (Transcranial Magnetic Stimulation, Electroconvulsive Therapy, Vagus Nerve Stimulation, tDCS), setting (Clinics, Hospitals, Home) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Neuromodulation for Depression market?
Key players include Neuronetics, BrainsWay, Magstim, LivaNova PLC and Flow Neuroscience.
What is driving the Neuromodulation for Depression market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the neuromodulation for Depression market. Governments and employers are investing more in mental health care.
Who regulates Neuromodulation for Depression in the UK?
Medical devices sold in Great Britain need UKCA or CE marking and registration with the Medicines and Healthcare products Regulatory Agency (MHRA). Source: Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.
How is healthcare paid for in the UK?
The NHS gives care that is free at the point of use; in England, NICE advises which medicines and treatments the NHS should fund. Source: National Institute for Health and Care Excellence. Checked 14 Nov 2026.
How many clinical trials on Neuromodulation for Depression are running in the UK?
5 studies are recruiting, active or about to start in the UK, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the UK. Retrieved 12 Nov 2026.
What does WHO report for the UK?
Suicide rate: 10.1 per 100,000 people in 2023, the latest WHO figure. Source: WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.
How many people in the UK are 65 or older?
19.7% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 15 Nov 2026.
Back to Catalogue

Related Medical Devices reports in UK

See all

Related on mental health and brain and nerves

See the topic